Role for epithelial dysregulation in early-onset colitis-associated colon cancer in Gi2-alpha-/- mice

Inflammatory Bowel Diseases

Volumn 14, Issue 7, 2008, Pages 898-907

  Edwards, Robert A ^a   Wang, Kehui ^a   Davis, Jennifer S ^a   Birnbaumer, Lutz ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Animal models of colon cancer; Colitis associated colon cancer; Heterotrimeric G protein signaling; Inflammatory bowel disease

Indexed keywords

ARACHIDONIC ACID; CAMPTOTHECIN; CASPASE 3; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL LINE; COLITIS; COLON CANCER; COLON MUCOSA; EPITHELIUM CELL; FEMALE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; ARACHIDONIC ACID; CELL LINE, TUMOR; COLITIS; COLONIC NEOPLASMS; EPITHELIUM; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; INFLAMMATORY BOWEL DISEASES; MICE;

EID: 47949130475     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20414     Document Type: Article

References (34)

1. Itzkowitz SH. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:553-571.
2. Odze RD. Pathology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:533-552.
3. Choi P, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994;35:950-954.
4. Itzkowitz SH. Inflammatory bowel disease and cancer. Gastroenterol Clin North Am. 1997;26:129-139.
5. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196-202.
6. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313-1316.
7. Rubin D, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:1346-1350.
8. Terdiman J, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:367-371.
9. Bernstein C, Nayar G, Hamel A, et al. Study of animal-borne infections in the mucosas of patients with inflammatory bowel disease and population-based controls. J Clin Microbiol. 2003;41:4986-4990.
10. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:675-712.
11. Edwards RA, Smock AZ. Defective arachidonate release and PGE2 production in Gia2-deficient intestinal and colonic subepithelial myofibroblasts. Inflamm Bowel Dis. 2006;12:153-165.
12. Rudolph U, Finegold MJ, Rich SS, et al. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet. 1995;10:143-150.
13. Inoue S, Hoshino S, Kukimoto I, et al. Purification and characterization of the G203T mutant alpha i-2 subunit of GTP-binding protein expressed in baculovirus-infected Sf9 cells. J Biochem (Tokyo). 1995;118:650-657.
14. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7-17.
15. Hirose Y, Yoshimi N, Makita H, et al. Early alterations of apoptosis and cell proliferation in azoxymethane-initiated rat colonic epithelium. Jpn J Cancer Res. 1996;87:575-582.
16. Aizu W, Guda K, Nambiar P, et al. p53 and its co-activator p300 are inversely regulated in the mouse colon in response to carcinogen. Toxicol Lett. 2003;144:213-224.
17. + and mitogen-activated protein kinase regulation. J Biol Chem. 1994;269:1889-1895.
18. Ilsley JN, Nakanishi M, Flynn C, et al. Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res. 2005;65:2636-2643.
19. Nakanishi M, Rosenberg DW. Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta. 2006;1761:1335-1343.
20. Murray-Whelan R, Reid JD, Piuz I, et al. The guanine-nucleotide-binding protein subunit G alpha i2 is involved in calcium activation of phospholipase A2. Effects of the dominant negative G alpha i2 mutant, [G203T]G alpha i2, on activation of phospholipase A2 in Chinese hamster ovary cells. Eur J Biochem. 1995;230:164-169.
21. Sordet O, Khan QA, Kohn KW, et al. Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents. 2003;3:271-290.
22. Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol. 1996;13:339-357.
23. Greenstein AJ, Slater G, Heimann TM, et al. A comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg. 1986;203:123-128.
24. Delaunoit T, Limburg PJ, Goldberg RM, et al. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:335-342.
25. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98:1010-1020.
26. Guest CB, Reznick RK. Colitis cystica profunda. Review of the literature. Dis Colon Rectum. 1989;32:983-988.
27. Maggio-Price L, Treuting P, Zeng W, et al. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res. 2006;66:828-838.
28. Zhu Y, Richardson JA, Parada LF, et al. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 1998;94:703-714.
29. Wu JY, Jin Y, Edwards RA, et al. Impaired TGF-beta responses in peripheral T cells of Galphai2-/- mice. J Immunol. 2005;174:6122-6128.
30. Gatalica Z, Torlakovic E. Pathology of the hereditary colorectal carcinoma. Fam Cancer. 2007 (in press).
31. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007;133:48-56.
32. Ishitsuka T, Kashiwagi H, Konishi F. Microsatellite instability in inflamed and neoplastic epithelium in ulcerative colitis. J Clin Pathol. 2001;54:526-532.
33. Ohman L, Franzen L, Rudolph U, et al. Immune activation in the intestinal mucosa before the onset of colitis in Galphai2-deficient mice. Scand J Immunol. 2000;52:80-90.
34. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying non-steroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A. 1998;95:681-686.